Metrics as of 10/13/2026, 06:40 PM (Berlin time), refresh in progress.
Novartis Stock
Novartis AG
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Switzerland
- CEO
- Vasant Narasimhan
- Employees
- 75,267
- Market cap
- $52.1 B
- IPO
- 22/10/2025
Novartis AG is a holding company that engages in the business of developing, manufacturing, and marketing healthcare products. The product portfolio of the company is heavily focused on innovative prescription medicines, especially in the areas of oncology, immunology, neuroscience, and cardiovascular diseases. These…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Novartis stock: price history
1D
+1.6%
1W
+3.0%
1M
+6.6%
6M
-0.5%
YTD
+9.3%
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~22% weaker price swings than usual
Ask the agents about Novartis
Free float & liquidity
FREE FLOAT
–
FLOAT SHARES
1,608,150,824
AVG. DAILY VOLUME (30D)
1,826
Dividends
Comparable stocks
Frequently asked questions about Novartis stock
What does Novartis do?
Novartis AG is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in Switzerland.
The CEO is Vasant Narasimhan, the company employs around 75,267 people.
The IPO was on 22/10/2025; the stock trades on TSX under the ticker NVS.TO.
When does Novartis report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does Novartis pay a dividend?
Yes. The last dividend was CA$0.57 per share, ex-date 11/03/2026, paid on 19/03/2026.
Which stocks are comparable to Novartis?
Comparable stocks include Roche Holding, Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Amgen, Gilead Sciences and Pfizer.
How can I get Novartis stock analyzed?
Clicking "Analyze stock" lets five strategies assess Novartis against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.